UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Determination of solubility limits of refractory elements in TCP phases of the Ni-Mo-Cr ternary system using diffusion multiples

Journal of alloys and compounds, 2019-06, Vol.788, p.67-74

2019

Link zum Volltext

Systematic Phase-Field Study on Microstructure Formation During Brazing of Mar-M247 with a Si-Based AMS4782 Filler

Metallurgical and materials transactions. A, Physical metallurgy and materials science, 2019-04, Vol.50 (4), p.1732-1747

2019

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SSCHN in clinical routine: Updated interim results of the prospective SOCCER study

Annals of oncology, 2018-10, Vol.29, p.viii379-viii380

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival – Results from a prospective, observational study in Germany

Breast (Edinburgh), 2014-10, Vol.23 (5), p.603-608

2014

Link zum Volltext

Verfügbarkeit prüfen

About Render: Designing and Realising Surfaces

1, 2023

Link zum Volltext

Verfügbarkeit prüfen

411P Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))

Annals of oncology, 2023-10, Vol.34, p.S355-S356

2023

Link zum Volltext

Verfügbarkeit prüfen

441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study

Annals of oncology, 2023-10, Vol.34, p.S366-S367

2023

Link zum Volltext

Verfügbarkeit prüfen

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Annals of oncology, 2023-08, Vol.34 (8), p.660-669

2023

Link zum Volltext

Verfügbarkeit prüfen

P-7 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria – BERING CRC

Annals of oncology, 2022-06, Vol.33, p.S248

2022

Link zum Volltext

Verfügbarkeit prüfen

5070 Real-life usage of capecitabine (X) for advanced breast cancer (ABC) in Germany: efficacy and safety results from a large (n = 870) non-interventional study

European journal of cancer supplements, 2009, Vol.7 (2), p.281-281

2009

Link zum Volltext

Verfügbarkeit prüfen

457P 1st-line panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany: Interim results of the non-interventional study VALIDATE

Annals of oncology, 2020-09, Vol.31, p.S436-S436

2020

Link zum Volltext

Verfügbarkeit prüfen

MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset

The New England journal of medicine, 2018-08, Vol.379 (7), p.611-622

2018

Link zum Volltext

Verfügbarkeit prüfen

6052 Capecitabine single agent or in combination in the routine first-line treatment of a predominantly elderly population with metastatic colorectal cancer (MCRC)

European journal of cancer supplements, 2009, Vol.7 (2), p.337-337

2009

Link zum Volltext

Verfügbarkeit prüfen

195P Impact of an interactive eHealth system for patient reported outcomes on safety in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy

ESMO open, 2023-05, Vol.8 (1), p.101384, Article 101384

2023

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial)

Annals of oncology, 2016-10, Vol.27, p.vi343-vi343

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Safety, Tolerability and Activity of Temsirolimus in Patients (Pts) with Advanced or Metastatic Renal Cell Carcinoma (A/Mrcc) in Routine Clinical Practice

Annals of oncology, 2014-09, Vol.25, p.iv296

2014

Link zum Volltext

Verfügbarkeit prüfen

FOLFOX / Bevacizumab (Beva) +/- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)

Annals of oncology, 2016-10, Vol.27, p.vi560-vi560

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-15-02: Trastuzumab treatment of early breast cancer: Long-term results from a prospective observation study, including a large cohort of elderly patients

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-15-02

2013

Link zum Volltext

Verfügbarkeit prüfen

Interim Analysis of Overall Survival Per Subgroups in the Prospective, Non-Interventional Insight Study in Patients with Hepatocellular Carcinoma Treated with Sorafenib

Annals of oncology, 2012-09, Vol.23, p.ix255-ix256

2012

Link zum Volltext

Verfügbarkeit prüfen

778TiP - Interim Analysis of Overall Survival Per Subgroups in the Prospective, Non-Interventional Insight Study in Patients with Hepatocellular Carcinoma Treated with Sorafenib

Annals of oncology, 2012-09, Vol.23, p.ix255-ix256

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 504

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(348)
Mit Volltextzugriff
(456)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(205)
Life Sciences & Biomedicine
(122)
Humans
(102)
Female
(59)
Physical Sciences
(59)
Technology
(52)
Male
(48)
Adult
(38)
Middle Aged
(33)
Materials Science
(31)
Science & Technology - Other Topics
(31)
Animals
(30)
Aged
(29)
Biological And Medical Sciences
(28)
Chemistry
(26)
Oncology
(25)
Physics
(25)
Materials Science, Multidisciplinary
(24)
Engineering
(19)
Microbiology
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Determination of solubility limits of refractory elements in TCP phases of the Ni-Mo-Cr ternary system using diffusion multiples

Systematic Phase-Field Study on Microstructure Formation During Brazing of Mar-M247 with a Si-Based AMS4782 Filler

Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SSCHN in clinical routine: Updated interim results of the prospective SOCCER study

Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival – Results from a prospective, observational study in Germany

About Render: Designing and Realising Surfaces

622P Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE

411P Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))

409P Treatment of elderly patients (pts; > 75 years) with 1st-line ribociclib (RIB) + endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))

441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study

P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

P-7 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria – BERING CRC

5070 Real-life usage of capecitabine (X) for advanced breast cancer (ABC) in Germany: efficacy and safety results from a large (n = 870) non-interventional study

457P 1st-line panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany: Interim results of the non-interventional study VALIDATE

MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset

6052 Capecitabine single agent or in combination in the routine first-line treatment of a predominantly elderly population with metastatic colorectal cancer (MCRC)

195P Impact of an interactive eHealth system for patient reported outcomes on safety in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy

216P What is driving treatment decision following 1st line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine? Real-world data from the RIBANNA study (6th interim analysis (IA))

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial)

Evaluation of Safety, Tolerability and Activity of Temsirolimus in Patients (Pts) with Advanced or Metastatic Renal Cell Carcinoma (A/Mrcc) in Routine Clinical Practice

FOLFOX / Bevacizumab (Beva) +/- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)

Abstract P2-15-02: Trastuzumab treatment of early breast cancer: Long-term results from a prospective observation study, including a large cohort of elderly patients

Interim Analysis of Overall Survival Per Subgroups in the Prospective, Non-Interventional Insight Study in Patients with Hepatocellular Carcinoma Treated with Sorafenib

778TiP - Interim Analysis of Overall Survival Per Subgroups in the Prospective, Non-Interventional Insight Study in Patients with Hepatocellular Carcinoma Treated with Sorafenib

Suchergebnisse filtern